top
HEREDITARY CANCERS

HEREDITARY CANCERS

Oncological disease, popularly known as cancer, is currently one of the most common diseases of affluence. Tumours arise from the uncontrolled proliferation of cells, which occurs randomly or as a result of an inherited mutation in a specific gene. According to the characteristics of the tumour and the prognosis of the disease, we distinguish between benign and malignant tumours, which are 10-15% hereditary. The most common cancers include breast and ovarian cancer, prostate cancer, colon cancer, pancreatic cancer, thyroid cancer and various types of leukaemia.

The hereditary disposition to cancer is inherited through mutations in important genes. There are a number of hereditary cancer syndromes (about 200). The most common are hereditary breast and ovarian cancer, hereditary colon cancer and hereditary prostate cancer, and then other lesser-known syndromes.

The purpose of genetic testing is to determine the level of risk of cancer. The result is used to set appropriate prevention and optimal treatment. If a risk variant is detected, preventive monitoring and predictive testing in the family is recommended as part of the genetic consultation. Cancer predisposition testing is for people after the age of 18 (exceptionally earlier). For people with a mutation at risk, it is possible to perform preimplementation diagnostics as part of the IVF and select a suitable embryo to prevent transmission of the mutation to the next generation.

BRCA1,2 Screen®

Pink October at GHC means a 50% discount with the code BRCA50 on the BRCA1,2 Screen® genetic analysis — available to the first 100 clients and for in-person sample collection only.

The test screens for 34 of the most common mutations in the BRCA1 and BRCA2 genes. In women, these mutations are associated with breast and ovarian cancer, while in men they increase the risk of prostate cancer. BRCA mutations can be inherited regardless of sex, which is why prevention is important for both women and men.

For in-person sample collection, please book an appointment and complete the genetic questionnaire before your visit.

We will send you the result within 15 business days from the receipt of the sample.

3 000 Kč

Hereditary breast and ovarian cancer syndrome

This genetic analysis examines in detail more than 2000 mutations in the entire BRCA1 and BRCA2 genes that cause breast and ovarian cancer in women and significantly increase the risk of prostate cancer in men. These mutations are inherited independently of gender, so prevention is absolutely key across the population. A genetic analysis will give you an answer as to whether you have a hereditary predisposition to the disease and, if necessary, allow you to take the necessary measures in time.

You will receive the result in 3-6 months.

25 000 Kč

Prostate cancer

Genetic analysis that can confirm or exclude a high risk of prostate cancer, which is one of the most frequently diagnosed cancers in men in the Czech Republic. Nearly eight thousand new cases are diagnosed annually. It is a cancer for which hereditary predispositions are a significant risk factor. Some of these cancers are caused by inherited cancer predispositions in risk genes. The result of the analysis will give you an answer as to whether you are at increased risk of developing this disease and, if necessary, allow you to take the necessary measures in time.

You will receive the result in 4-5 months.

20 000 Kč

Tumour syndromes

Genetic analysis of 88 risk genes that are associated with certain inherited diseases, particularly breast and ovarian, colorectal, pancreatic, prostate and other cancers. The genetic analysis result will give you an answer as to whether you have a hereditary predisposition to cancer and, if necessary, allow you to take the necessary measures in time. A number of factors are involved in the development of tumours; apart from hereditary predispositions, these include external influences and lifestyle factors.

You will receive the result in 3-6 months.

35 000 Kč

CZECANCA

The CZECANCA panel (CZEch CAncer paNel for Clinical Application) is a detailed genetic analysis for the investigation of cancer predisposition. It examines a broad spectrum of hereditary cancers, currently including 226 target genes, which are constantly updated. The CZECANCA panel was developed by the group of doc. MUDr. Kleibl from the Institute of Biochemistry and Experimental Oncology, 1st Medical Faculty of Charles University in Prague. The results of the tests allow mapping of risk mutations in the Czech population and give you an answer whether you are at high risk of developing cancer.

You will receive the result within 1– 2 months.

40 000 Kč

Predictive testing for mutations in the family

Genetic analysis of high-risk mutations in hereditary cancer genes, especially suitable for relatives (parents, siblings, children) of a person with a high-risk mutation or who has been diagnosed with cancer. It will allow you to find out if you are at risk of developing cancer. Based on the results of the analysis, you will be recommended for preventive monitoring and, if a risk mutation is found, genetic testing will be recommended for other blood relatives at risk. If a member of your family has been diagnosed with a risk predisposition (gene mutation), the test is covered by public health insurance.

You will receive the result within 3 months.

5 000 Kč

PulmoScreen

A non-invasive blood test enables early detection of lung cancer by identifying specific biomarkers. Early diagnosis significantly increases the chances of successful treatment — the five-year survival rate for early-stage cases reaches up to 92%. The test is suitable for smokers, individuals over 40, patients with lung diseases, or those with a family history of cancer.

You will receive the result within 15 working days.

4 900 Kč

ColonScreen

A non-invasive screening test allows for the detection of colorectal cancer (cancer of the colon and rectum) at an early stage, even before symptoms appear. The test works by detecting biomarkers in the patient’s blood and is suitable for individuals with risk factors or a family history of the disease. Early diagnosis significantly increases the chances of successful treatment.

You will receive the result within 15 working days.

4 800 Kč

MLPA analysis

MLPA analysis MLPA (MRC Holland) detects deletions and duplications of single exons or whole genes that routine sequencing misses. We test with MRC Holland probemixes for hereditary cancer genes (e.g. BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, APC) and other hereditary disorders. As an MRC Holland service laboratory we provide testing to clinicians, laboratories and patients, from our own sampling or from isolated DNA you send us.

5 000 Kč

Frequently Asked Questions

The time required for the laboratory examination (sample analysis) and the delivery date of the result vary according to the type and complexity of the examination. Usually it is in the order of weeks, for complex tests up to several months. The delivery date of the result is indicated in the details of each test on our website. In urgent situations, e.g. for a woman with a newly diagnosed breast or ovarian tumour before surgery, the oncopanel cancer test is performed in STATIM mode and the result is available within 3-4 weeks, whereas in normal mode it takes up to 6 months.
Health insurance always covers genetic consultations recommended by the attending physician (usually a general practitioner, paediatrician, oncologist, gynaecologist or other specialist). During the consultation, a clinical geneticist will assess whether the indication criteria for testing for the predisposition genes are met; if so, the entire genetic test, including laboratory analysis of the sample and subsequent consultation with the geneticist/doctor, is covered by health insurance. If the criteria for the genetic testing are not met, the patient can pay for the selected/recommended test as a self-payment.
After making an appointment, first fill out our personal and family history questionnaire HERE on our website. This is followed by a consultation with a doctor who will compile your three-generation family tree and decide on the indication for laboratory genetic testing. We also recommend that you bring medical reports from recent important examinations.
Recommendation – a referral from the doctor who recommended the genetic consultation. Medical reports from previous examinations related to the requested genetic test. It is not necessary to be fasting for the genetic examination, so you can easily make an appointment in the afternoon. Do not forget to fill out online genetic family and personal history questionnaire before your visit, which you can find HERE.
By phone at 800 390 390 or 234 280 280, by e-mail at info@ghcgenetics.cz.
It has been reported that approximately 5-10% of cancers are caused by inborn changes in certain genes. One of the main goals of predictive genetic testing is the early identification of people at risk. If risk predispositions (gene mutations) are detected, preventive follow-up at specialised centres is recommended, where possible cancers are detected early and the chances of successful treatment are increased. In the case of high-risk mutations, preventive surgery may be recommended to make the risk of cancer in a given organ virtually impossible (for example, removal of the breast glands or removal of the uterus and ovary in BRCA1 or BRCA2 mutation carriers).
If your first-degree relative (parents, siblings, children) develops colon cancer before the age of 45, your risk of developing this cancer is 5 times higher. If you have three first-degree relatives, your risk can be as high as 50%. In families with a history of recurrent bowel cancer or with a history of bowel cancer at a young age, it could be hereditary cancer syndrome (Lynch syndrome). In such cases, genetic consultation is recommended.

Do you have a question or don't know which test to choose?

Call us at 800 390 390 or contact us and we'll be happy to help.